对SARS-CoV-2,SARS-CoV,MERS-CoV和HCoV-229E的比较转录组分析确定了抑制病毒复制的潜在IFN/ISG标

Yuzhuang Liu1, Tianyi Lu2,3, Cuidan Li2

  • 1National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.

Frontiers in medicine
|December 25, 2023
PubMed
概括

严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 引发了比SARS-CoV和MERS-CoV更强的免疫反应和更大的多器官毒性风险. 干扰素刺激基因 (ISG) 是阻碍SARS-CoV-2的关键,提供潜在的治疗点.